ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0289

Patient Preferences Study for Treatments of Anemia in CKD Patients Not on Dialysis (NDD)

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Alexandre, Ana filipa, Astellas Pharma Europe B.V., Leiden, Netherlands
  • Morga, Antonia, Astellas Pharma Europe Ltd, Addlestone, United Kingdom
  • Thomas, Caitlin, Evidera, London, United Kingdom
  • Krucien, Nicolas, Evidera, London, United Kingdom
  • Tervonen, Tommi, Evidera, London, United Kingdom
  • Jiletcovici, Alina, Astellas Pharma, Inc., Northbrook, Illinois, United States
  • Marsh, Kevin Patrick, Evidera, London, United Kingdom

Erythropoietin analogues (EAs) are a mainstay of treatment of anemia in adult patients with CKD but they are associated with increased risk of cardiovascular (CV) events. Furthermore, their mode of administration (intravenous or subcutaneous [SC]) may represent a barrier to some patients. As such, the aim of this study was to understand patients’ valuation of attributes associated with CKD anemia treatments.


Adult (≥18 years) patients from UK, Spain, Germany, and France, who had self-reported NDD CKD anemia and were being treated with EAs, participated in this online discrete choice experiment (DCE). Patients were presented with choice tasks, each with two anemia treatment options described in terms of five attributes (mode of administration, need for iron supplementation, risk of gastrointestinal [GI] side effects, risk of major CV events, and impact on energy levels). A multinomial logit model with an error component was used to analyze participants’ choices and estimate their treatment preferences. Estimated preferences were used to determine maximum level of CV and GI risk that patients were willing to tolerate to improve other treatment features.


Between November 2019 and March 2020, 200 eligible patients (53% male) completed the DCE survey. The mean (SD) age was 53.78 (12.73) years; patients had been diagnosed with CKD 6.02 (7.49) years prior, and with CKD anemia 3.45 (3.44) years prior. Patients were found, on average, to value each of the five attributes associated with the treatments of CKD anemia. Patients were willing to tolerate a 5.12% (95% CI: 1.99; 8.25) increase in the risk of a major CV event and an 11.73% (95% CI: 4.96; 18.50) increase in the risk of GI side effects to switch from an at-home SC injection administered once every 2 weeks to an at-home oral pill administered three times a week. Patients would be willing to tolerate a 20.31% increase in the risk of GI side effects and an 8.86% increase in the risk of a major CV event to move from sometimes having a lot of energy to always having a lot of energy.


Patients would be willing to tolerate increased risks of CV and GI events to obtain an oral treatment for NDD CKD anemia and to always have a lot of energy.


  • Commercial Support